Steunebrink Laura M M, Versteeg Letty G A, Vonkeman Harald E, Ten Klooster Peter M, Hoekstra Monique, van de Laar Mart A F J
1Arthritis Center Twente, Department of Rheumatology, Medisch Spectrum Twente, PO BOX 50 000, 7500 KA Enschede, The Netherlands.
2Department of Psychology, Health & Technology, University of Twente, Enschede, The Netherlands.
BMC Rheumatol. 2018 Jan 17;2:1. doi: 10.1186/s41927-018-0009-8. eCollection 2018.
Early and intensive targeted treatment with disease modifying anti-rheumatic drugs (DMARDs) has been shown to lead to substantial reductions in disease activity and radiograph damage in patients with early rheumatoid arthritis (RA). The aim of this quasi-experimental study was to compare the first-year radiographic progression rates between a treat-to-target (T2 T) strategy with initial combination therapy (strategy II, started in 2012) versus an initial step-up monotherapy (strategy I, started in 2006).
A total of 128 patients from strategy II was individually matched with 128 patients from strategy I on sex, age (± 5 yrs.) and baseline disease activity (± 0.5 on the DAS28). Differences in radiographic progression (Sharp/van der Heijde) scores (SHS) and the number of patients experiencing a minimal clinically important difference (MCID; ≥ 5 SHS points) between both strategies were tested with Mann Whitney U and chi-square tests. Next, linear and logistic regression analyses were performed to examine which baseline variables were associated with radiographic progression scores and the probability of experiencing an MCID within 1 year.
Patients with initial combination therapy had slightly higher baseline disease activity scores and pain scores, but better mental health scores. Patients with initial monotherapy had significantly more, and more frequently clinically relevant, radiographic progression after 1 year. Experiencing a MCID was independently associated with fewer tender joints ( = 0.050) and higher erythrocyte sedimentation rate ( = 0.015) at baseline.
Treating early RA patients with initial combination therapy results in better radiographic outcomes than initial monotherapy in daily clinical practice.
Netherlands Trial Register NTR578, 12 January 2006.
已有研究表明,早期类风湿关节炎(RA)患者采用早期强化靶向治疗,使用改善病情抗风湿药(DMARDs)可显著降低疾病活动度和影像学损伤。本准实验研究旨在比较初始联合治疗的达标治疗(T2T)策略(策略II,于2012年开始)与初始逐步递增单药治疗(策略I,于2006年开始)之间的第一年影像学进展率。
从策略II中选取128例患者,与策略I中的128例患者在性别、年龄(±5岁)和基线疾病活动度(DAS28评分±0.5)方面进行个体匹配。采用Mann-Whitney U检验和卡方检验,比较两种策略在影像学进展(Sharp/van der Heijde)评分(SHS)以及出现最小临床重要差异(MCID;≥5 SHS分)的患者数量方面的差异。接下来,进行线性和逻辑回归分析,以检验哪些基线变量与影像学进展评分以及1年内出现MCID的概率相关。
初始联合治疗的患者基线疾病活动度评分和疼痛评分略高,但心理健康评分更好。初始单药治疗的患者在1年后影像学进展显著更多,且在临床上更常见。基线时出现MCID与较少的压痛关节数(=0.050)和较高的红细胞沉降率(=0.015)独立相关。
在日常临床实践中,早期RA患者采用初始联合治疗比初始单药治疗能带来更好的影像学结果。
荷兰试验注册NTR578,2006年1月12日。